33 completed, 15 recruiting, 14 active not recruiting, 7 terminated. 37 Phase 2, 18 Phase 1, 7 Not applicable, 7 Phase 3, 1 Early Phase 1.
Follow Ureteral Neoplasms: new trials by email Literature Review of Ureteral Neoplasms trials Research Report on Ureteral Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer Quemliclustat, Biospecimen Collection, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 27 | 2026-10-20 | 2026-10-22 |
| Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers Best Practice, Biospecimen Collection, Central Venous Cannula Insertion - Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 70 | 2025-08-01 | 2026-05-08 |
| Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer PD-1 inhibitior, Nab-paclitaxel, distal ureterectomy - Ureteral Cancer, Neoadjuvant Therapy | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 35 | 2025-07-05 | 2025-08-15 |
| Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer copanlisib, Avelumab - Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Withdrawn | VA Office of Research and Development | 2025-06-02 | 2025-06-15 | |
| Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy - Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter | Phase 2 | Recruiting | Nagoya University | 43 | 2025-05-01 | 2025-08-14 |
| Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial Biospecimen Collection, Computed Tomography, Cystectomy - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma | Phase 4 | Recruiting | Mayo Clinic | 75 | 2025-01-08 | 2026-10-01 |
| Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria Hematuria, Urothelial Carcinoma | Not yet recruiting | Changhai Hospital | 1200 | 2024-07-01 | 2024-07-05 | |
| A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors LY4052031, Pembrolizumab - Metastatic Solid Tumor, Recurrent Solid Tumor | Phase 1 | Recruiting | Eli Lilly and Company | 460 | 2024-07-01 | 2026-10-22 |
| Urine DNA Methylation Detection for Hematuria Evaluation Hematuria, Urothelial Carcinoma | Unknown | Changhai Hospital | 71 | 2024-06-15 | 2024-06-20 | |
| Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery spinal analgesia with morphine and bupivacaine, lidocaine infusion - Other Specified Disorders of Kidney and Ureter, Benign Neoplasm of Ureter | Phase 3 | Recruiting | Hans Bahlmann | 220 | 2024-04-09 | 2026-02-05 |
| A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors LY4101174 - Metastatic Solid Tumor, Recurrent Solid Tumor | Phase 1 | Active not recruiting | Eli Lilly and Company | 490 | 2024-03-05 | 2026-05-22 |
| Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology Biospecimen Collection, Computed Tomography, Enfortumab Vedotin - Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma | Phase 2 | Recruiting | Emory University | 25 | 2023-09-26 | 2026-07-29 |
| The Efficacy and Safety of Chinese Domestic Surgical Robot System in Urological Telesurgery telesurgery by domestic surgical robot - Renal Cell Carcinoma, Adrenal Tumor | Not applicable | Unknown | The Affiliated Hospital of Qingdao University | 100 | 2023-02-05 | 2023-07-14 |
| FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 Vepugratinib, Pembrolizumab, enfortumab vedotin - Urinary Bladder Neoplasms, Neoplasm Metastasis | Phase 1 | Recruiting | Eli Lilly and Company | 677 | 2023-01-12 | 2026-08-20 |
| Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome Urological Malignancies, Prostate Cancer | Recruiting | Yonsei University | 3000 | 2022-12-19 | 2023-01-31 | |
| Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy Biospecimen Collection, Bone Scan, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2022-07-07 | 2026-09-22 |
| Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study Avelumab, Biospecimen Collection, Bone Scan - Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 654 | 2022-06-03 | 2026-10-01 |
| Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs Systematic therapy combined with radiotherapy, Systematic drug treatment - Oligometastatic Disease, Ureter Cancer | Not applicable | Recruiting | Peking University First Hospital | 102 | 2022-01-01 | 2024-10-22 |
| Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC Immunotherapy+radiotherapy, surveillance alone - Ureter Cancer, Renal Pelvic Carcinoma | Recruiting | Peking University First Hospital | 60 | 2022-01-01 | 2024-11-05 | |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
Showing 20 of 79. Sign in to see all of them.
Urinary Bladder Neoplasms (61) · Urethral Neoplasms (41) · Carcinoma, Transitional Cell (32) · Carcinoma, Renal Cell (10) · Prostatic Neoplasms (9) · Carcinoma, Non-Small-Cell Lung (7) · Kidney Neoplasms (7) · Pancreatic Neoplasms (6) · Urologic Neoplasms (6) · Esophageal Neoplasms (5) · Lung Neoplasms (5) · Melanoma (5) · Neoplasm Metastasis (5) · Ovarian Neoplasms (5)
Female Urogenital Diseases (79) · Female Urogenital Diseases and Pregnancy Complications (79) · Male Urogenital Diseases (79) · Urogenital Diseases (79) · Urologic Diseases (79) · Neoplasms by Site (78) · Ureteral Diseases (78) · Urogenital Neoplasms (78) · Neoplasms (76) · Urologic Neoplasms (73) · Urinary Bladder Diseases (61) · Neoplasms by Histologic Type (46) · Neoplasms, Glandular and Epithelial (45) · Carcinoma (43) · Urethral Diseases (41)
Gemcitabine (13) · pembrolizumab (11) · Specimen Handling (10) · enfortumab vedotin (9) · Cisplatin (8) · Magnetic Resonance Spectroscopy (8) · Carboplatin (5) · avelumab (5) · Biopsy (4) · Nivolumab (4) · vinflunine (4) · Disulfides (3) · Immunoglobulin G (3) · atezolizumab (3) · 1,2-diaminocyclohexaneplatinum II citrate (2)
National Cancer Institute (NCI) (12) · Eli Lilly and Company (5) · M.D. Anderson Cancer Center (5) · Mayo Clinic (4) · Asan Medical Center (3) · Changhai Hospital (3) · Astellas Pharma Global Development, Inc. (2) · Dr Anders Ullén (2) · Emory University (2) · Fox Chase Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · Peking University First Hospital (2) · Yonsei University (2) · AEterna Zentaris (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)
United States (55) · China (11) · Spain (11) · Canada (10) · France (10) · South Korea (10) · Japan (8) · Germany (7) · Italy (7) · United Kingdom (7) · Australia (5) · Denmark (4) · Netherlands (4) · Sweden (4) · Austria (2)
Andrea B Apolo (2) · Andrea B Apolo, M.D. (2) · Jacob J. Orme, MD, PhD (2) · Jacqueline Brown, MD (2) · Abhishek Tripathi, MD (1) · Anishka A D'Souza (1) · Arlene Siefker-Radtke (1) · Arlene Siefker-Radtke, MD (1) · Betty Ferrell (1) · Changting Meng, MD (1) · Chong-Xian Pan, MD PhD (1)
PMID 11001674, PMID 11844814, PMID 1607913, PMID 16330205, PMID 16849761, PMID 18024869, PMID 18685414, PMID 19687335, PMID 22012004, PMID 23329066, PMID 23835707, PMID 24055428, PMID 26001531, PMID 26926681, PMID 27328856, PMID 29149611, PMID 29415874, PMID 29853658, PMID 30552156, PMID 31301962, PMID 31356140, PMID 31390274, PMID 31648851, PMID 32915679, PMID 33037018, PMID 33046869, PMID 33068794, PMID 33577729, PMID 33989025, PMID 33991512, PMID 34030643, PMID 35031545, PMID 35168844, PMID 35537412, PMID 36041086, PMID 37328287, PMID 37369081, PMID 38215355, PMID 38418343, PMID 38849479, PMID 38954785, PMID 39282902, PMID 40256659, PMID 40591902, PMID 42091145
U10CA031946 (3), U10CA180821 (3), 2017 (2), 2023 (2), P30CA016672 (2), P30CA138292 (2), UM1CA186717 (2), 2015 (1), N01CM00038 (1), P30CA014599 (1), P30CA015704 (1), P30CA093373 (1), U01CA154967 (1), UM1CA186644 (1), UM1CA186712 (1)